BRNS
Barinthus Biotherapeutics plc.
Key Financials
Operating Income
$-70555000
↓ 3.8%
Net Income
$-66428000
↓ 8.8%
Total Liabilities
$23.9M
↓ 20.9%
Shareholders' Equity
$74.2M
↓ 42.9%
Total Assets
$98.2M
↓ 38.8%
Revenue
$0
↓ 100.0%
EPS (Diluted)
$-1.64
↓ 5.8%
Cash & Equivalents
$70.5M
↓ 36.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 15-12G | 9/21/2026 | View on SEC |
| EFFECT | 9/14/2026 | View on SEC |
| SCHEDULE 13G/A | 9/11/2026 | View on SEC |
| 4/A | 9/11/2026 | View on SEC |
| 25 | 9/9/2026 | View on SEC |
| 4 | 9/9/2026 | View on SEC |
| 4 | 9/9/2026 | View on SEC |
| 4 | 9/9/2026 | View on SEC |
| 4 | 9/9/2026 | View on SEC |
| 4 | 9/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BRNS |
| Company Name | Barinthus Biotherapeutics plc. |
| CIK | 1828185 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | X0 |
| Phone | 44 (0) 1865 818808 |